Rockefeller Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.27M Buy
47,933
+467
+1% +$44.9K 0.01% 1067
2026
Q2
$4.21M Sell
47,466
-16,536
-26% -$1.21M 0.01% 1047
2026
Q1
$3.23M Buy
64,002
+63,453
+11,558% +$2.39M 0.01% 1095
2025
Q4
$18K Buy
549
+148
+37% +$3.87K ﹤0.01% 3560
2025
Q3
$6.72K Buy
+401
New +$6.54K ﹤0.01% 3785

Other funds holding SYRE

Rockefeller Capital Management's SYRE Position: Q3 2026 in Review

Rockefeller Capital Management increased its Spyre Therapeutics (SYRE) stake by 0.98% in Q3 2026, buying an estimated $44.9K and bringing the position to 47,933 shares worth $4.27M. The position accounts for 0.01% of the portfolio, ranked #1067.

Rockefeller Capital Management first reported a position in SYRE in Q3 2025 and has held it in 5 quarters since. 286 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • Rockefeller Capital Management held 47,933 shares of Spyre Therapeutics worth $4.27M as of Q3 2026.
  • Rockefeller Capital Management bought 467 Spyre Therapeutics shares in Q3 2026, an estimated $44.9K.
  • Spyre Therapeutics made up 0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #1067 holding.
  • Rockefeller Capital Management first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • 286 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.